Turkish PASE: Turkish Version of the Psoriatic Arthritis Screening and Evaluation Questionnaire
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Psoriatic arthritis (PsA) is an inflammatoryarthritis associated with psoriasis and causes irreversiblejoint damage, unless detected early and treated with systemicdrugs. Objective: There is no reliable tool for screeningPsA among Turkish psoriasis patients. Therefore, we aimedto validate the psoriatic arthritis screening and evaluation(PASE) questionnaire in the Turkish. Methods: A 15-itemTurkish PASE questionnaire was administered to 122consecutive psoriasis patients who visited our dermatologyclinic for routine evaluations. Then, the patients wereevaluated for PsA by a rheumatologist who was blinded tothe results of the questionnaire. Results: Among the 113patients who participated in the study, 11.5% (13 of 113) hada diagnosis of PsA. The Turkish PASE total scores ranged from15 to 67 (possible range, 15∼75). The median total scorewas 49 (25th and 75th percentile, 36 and 50) for the PsAgroup and 35 (25th and 75th percentile, 27 and 42) for thenon-PsA group. The median total score of the PsA group wassignificantly higher than that of the non-PsA group (p=0.33). The Turkish PASE total score of 44 distinguished PsA fromnon-PsA participants, with 62% sensitivity and 76% specificity. For further analysis of each question, we counted theresponses according to symptoms (positive for “agree” and“strongly agree” and negative for “disagree” and “stronglydisagree”), and the sensitivity ranged from 23% (third questionof the functions subscale) to 77% (second question of thesymptoms subscale, first and fifth questions of the functionssubscale) and the specificity ranged from 51% (second questionof the symptoms subscale) to 87% (fourth question ofthe functions subscale). No relation was found between thePASI scores and the presence (p=0.899) or absence (p=0.941) of PsA, as well as between the PASI and PASE scoresof each patient (p=0.961). Conclusion: Thirteen of the 15items demonstrated significant test-retest reliability as assessedwith the Spearman correlation coefficient (p＜0.05). These results show that the Turkish version of the PASEquestionnaire may be useful for identifying PsA patients forinclusion in trials; however, it is not a reliable tool for screeningPSA patients in a dermatology clinic.
Abstract
Background: Psoriatic arthritis (PsA) is an inflammatoryarthritis associated with psoriasis and causes irreversiblejoint damage, unless detected early and treated with systemicdrugs. Objective: There is no reliable tool for screeningPsA among Turkish psoriasis patients. Therefore, we aimedto validate the psoriatic arthritis screening and evaluation(PASE) questionnaire in the Turkish. Methods: A 15-itemTurkish PASE questionnaire was administered to 122consecutive psoriasis patients who visited our dermatologyclinic for routine evaluations. Then, the patients wereevaluated for PsA by a rheumatologist who was blinded tothe results of the questionnaire. Results: Among the 113patients who participated in the study, 11.5% (13 of 113) hada diagnosis of PsA. The Turkish PASE total scores ranged from15 to 67 (possible range, 15∼75). The median total scorewas 49 (25th and 75th percentile, 36 and 50) for the PsAgroup and 35 (25th and 75th percentile, 27 and 42) for thenon-PsA group. The median total score of the PsA group wassignificantly higher than that of the non-PsA group (p=0.33). The Turkish PASE total score of 44 distinguished PsA fromnon-PsA participants, with 62% sensitivity and 76% specificity. For further analysis of each question, we counted theresponses according to symptoms (positive for “agree” and“strongly agree” and negative for “disagree” and “stronglydisagree”), and the sensitivity ranged from 23% (third questionof the functions subscale) to 77% (second question of thesymptoms subscale, first and fifth questions of the functionssubscale) and the specificity ranged from 51% (second questionof the symptoms subscale) to 87% (fourth question ofthe functions subscale). No relation was found between thePASI scores and the presence (p=0.899) or absence (p=0.941) of PsA, as well as between the PASI and PASE scoresof each patient (p=0.961). Conclusion: Thirteen of the 15items demonstrated significant test-retest reliability as assessedwith the Spearman correlation coefficient (p＜0.05). These results show that the Turkish version of the PASEquestionnaire may be useful for identifying PsA patients forinclusion in trials; however, it is not a reliable tool for screeningPSA patients in a dermatology clinic.
참고문헌 (9)
- Stern RS, "The epidemiology of joint complaints in patients with psoriasis", J Rheumatol, 12, pp.315~320 (1985)
- Feldman SR, "New topical treatments change the pattern of treatment of psoriasis: dermatologists remain the primary providers of this care", Int J Dermatol, 39, pp.41~44 (2000)
- Congi L, "Clinical application of the CASPAR criteria for psoriatic arthritis compared to other existing criteria", Clin Exp Rheumatol, 28, pp.304~310 (2010)
- Veale DJ, "Psoriatic arthritis--pathogenesis and epidemiology", Clin Exp Rheumatol, 20(6 Suppl 28), pp.S27~S33 (2002)
- Husni ME, "The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool", J Am Acad Dermatol, 57, pp.581~587 (2007)
- Dominguez PL, "Validity, reliability, and sensitivity-to-change properties of the psoriatic arthritis screening and evaluation questionnaire", Arch Dermatol Res, 301, pp.573~579 (2009)
- Alenius GM, "Inflammatory joint manifestations are prevalent in psoriasis: prevalence study of joint and axial involvement in psoriatic patients, and evaluation of a psoriatic and arthritic questionnaire", J Rheumatol, 29, pp.2577~2582 (2002)
- Gladman DD, "Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS)", Ann Rheum Dis, 68, pp.497~501 (2009)
- Moll JM, "Psoriatic arthritis", Semin Arthritis Rheum, 3, pp.55~78 (1973)